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ABSTRACT
Objective: The feasibility of neoadjuvant
chemotherapy for clinically unresectable gastric and 
gastroesophageal (GE) junction cancers.
Methods: Eleven patients with gastric and GE junction 
cancers underwent preoperative combined modality 
chemo and radiotherapy and a subsequent attempt for 
surgical resection.
Results: Combined modality periadjuvant therapies 
downsized 9 of 11 T3-4 gastric and gastroesophageal 
junction cancers and produced 4 pathologically proven 
complete remissions. Treatment appeared to convert 
lymph nodes to a cancer free status for 7 of 11 
patients. After treatment, exploratory surgery found 
that 3 patients had only minute foci of occult metastatic 
disease. The quality of the responses was 
underestimated by both endoscopic ultrasound and 
CT scans. Responses were sometimes only achieved 
after 2-3 months of therapy.
Conclusion: Combined modality therapy
demonstrates the feasibility of a flexible multistep 
approach to neoadjuvant therapy incorporating new 
drugs such as methotrexate and hydroxyurea in 
addition to fluorouracil and cisplatin. Long delays in 
surgery (gastrectomy) appear to be safe in the context 
of combined modality therapy. Median survival 
exceeds 2 years. The experience suggests new early 
end points for evaluation of neoadjuvant treatments: 
quality of life, quality of lymph node sterilization and 
extent of required gastrectomy in comparison to 
standard surgery.
Key W ords: Neoadjuvant, Gastric cancer, 
Gastroesophageal cancer, Combined modality 
treatment
INTRODUCTION
Advanced T 3-4 adenocarcinomas of the stomach and 
gastroesophageal junction present a difficult challenge 
and vast majority of patients fail conventional therapy. 
Forty five -66% of these patients have unresectable, 
locally advanced tumors (1). Patients with T4 tumors 
usually have (75-95%) disease in the lymph nodes and 
only a 15% or less chance of long disease free survival
(2).
Phase II trials of preoperative treatment, when 
compared to historical surgical results, find a 10-20 % 
rate of pathologically proven complete response, 
improved rates of resectability approaching 60-80%, 
and 20-30 % improvement in disease free survival 
over 2-3 years (3-5). These recent trials describe 
median survivals of 9-18 months (3,5-8). Preoperative 
treatment while increasing in frequency of use, has 
not achieved the status of standard therapy.
Post operative adjuvant therapy remains controversial
(1,9,10). Some trials combining 5Fluorouracil- 
Mitomycin C and immunotherapy appear to find 
modest benefit (9). A positive impact due to 
chemotherapy has only infrequently been described; it 
is usually found only for the subgroup of patients with 
a poor prognosis, due to their advanced invasive 
tumors (1,9). These are the same patients considered 
candidates for trials of preoperative treatment.
Relapse occurs with 90% frequency even when 
surgery is technically successful for patients with 
similar but less advanced tumors (2,3,5,6). T4 size, 
invasion of adjacent structures , proximal tumor 
location, poor grade and presence of symptoms due to 
the primary tumor all imply that the patient will have an 
extremely poor prognosis following conventional 
surgery alone (3). The recent availability of accurate 
preoperative staging with endoscopic sonography (11)
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and improved (spiral) CT scans further strengthens 
these prognostic factors.
METHODS
Eligibility: Patients were required to have T3-4, NX or 
1 and MO tumors clinically. They were also required to 
have biopsy proven adenocarcinoma of the stomach 
or GE junction crossing the Z line. The evaluation 
required evidence of invasive cancer on biopsy, 
without radiographic evidence of metastatic disease 
on CT scan. The tumors could not appear to be easily 
resectable or carry a greater than 25% surgical 
prognosis for long term ( 2-3 year) survival. All patients 
gave informed consent for preoperative treatment. 
Endoscopic sonography was used as needed to clarify 
the extent of the invasion, the size and the operability 
of the tumor. Patient characteristics are shown in 
Table IA.
Radiation Methods: Radiation was delivered by a 
linear accelerator, utilizing 6 or 15 mV photons.
Table I A . Patient Characteristics (n=11)
Age(yr) 64 (40-82)
Sex: Male/Female 7/4
Performance Status
1 3
2 6
3 2
Location of Tumors:
Gastro-Esophageal Junction 2
Proximal 2
Fundus 3
Corpus 1
Distal 3
Histologic Grade
Well differentiated -
Moderately differentiated 5
Poorly differentiated 6
Clinical Primary Stage
T3 (penetrates the serosa) 3
T4 (invades adjacent structures) 8
No. underwent surgery 11
No. resected 9
Patients underwent treatment planning CT scans and 
fields were tailored to the site and nodal group utilizing 
a 2, 3 or 4 field technique. Care was taken to limit dose 
to the spine, kidney and liver with cerrobend shaped 
fields in all cases. Except for 2 cases of bid radiation, 
daily doses of 180 cGy were given either continuously 
and simultaneously with chemotherapy or in a split 
course with simultaneous chemotherapy with 2 week 
rest periods between courses. The radiation was 
given with chemoterapy in a preoperative intent and 
total doses ranged from 3240 cGy to 4500 cGy. Total 
dose and number of courses was in part determined 
by safety and course assessment of the degree of 
down sizing of primary tumor.
Staging: Patients were staged initially, restaged after 
2 and 3 cycles of therapy and again 3 weeks after the 
end of radiotherapy. Tests included CT or MRI scan, 
as well as endoscopy and endoscopic sonography as 
needed. Surgical and pathological evaluation followed 
completion of treatment.
Treatment Selection: Treatment was selected 
individually as follows: Initially chemotherapy alone for 
patients with the worst stage (T4), and the elderly (>75 
years). Methotrexate, Calcium Leucovorin, 
Cisplatinum, 5- Fluorouracil (MLPF) for those with 
good performance status and tumors not in 
gastroesophageal junction or proximal stomach, 
Cisplatinum, Calcium Leucovorin, 5- Fluorouracil 
(PLF) for intermediate performance status and 
Methotrexate, Calcium Leucovorin, 5- Fluorouracil 
(MLF) for patients with numerous kinds of poor 
(chemotherapy) risk factors. Radiotherapy was added 
with additional chemotherapy if this failed to 
downstage tumors. Combined modality was attempted 
from the onset of therapy in patients with good 
performance status considered good risk for combined 
modality therapy, especially those with 
gastroesophageal junction or proximally located 
tumors. Distal tumors were initially treated with 
chemotherapy, radiation therapy was added, used 
simultaneously with chemotherapy as needed.
Treatment Evaluation: Pathological complete
remission was defined as absence of carcinoma cells 
on microscopical examination of the surgically 
resected specimen. Clinical complete remission was 
defined as no evidence of disease on either 
radiological, endoscopic or serological assays prior to 
a surgical exploration. Minimal residual disease (m in 
table) defines surgical finding of lesions that are less 
than 0.5 cm in greatest diameter. Partial response was 
defined as a 50% or greater reduction in tumor volume 
(product) evident by radiographs, endoscopy, or 
computerized tomography. Minor response was 
defined as an objective but less than 50% regression
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in product of tumor diameters. The purpose for 
defining minor clinical responses was the identification 
of patients who would receive further preoperative 
Combined Modality Therapy (CMT) and postoperative 
chemotherapy and ultimately to correlate these 
responses with outcome measures. Survival was 
measured from the date of registration to the date of 
death. Patients were assessed every 3 months for the 
first year following completion of all therapy. They were 
then examined every 6 months for 4 additional years.
Statistical Methods: Survival was examined in 
absolute terms. No actuarial projections were used, in 
order to avoid an unrealistic inflation of outcome 
analyses. This is an intent to treat analysis with no 
known exclusions. A prospective data base was 
available for identification of candidates.
Toxicity: Cancer and Leukemia Group B (CALGB) 
common toxicity c r ite r ia  w e re  u s e d  fo r assessment of 
toxicity. The Zubrod performance scale was used for 
evaluation of performance status.
Table I B. Disease characteristics of patients.
RESULTS
Table IB shows the characteristics of the 11 patients; 
their sites of residual disease and their degree of 
response. There were 4 pathological complete 
remissions. 3 patients had minute foci of occult 
metastatic disease. Nine of 11 patients were 
resectable, and in spite of an extensive search for 
lymph node metastasis only 1 patient had tumor in a 
lymph node. Five patients had residual resectable 
local disease. All patients with major responses had 
minimal residual disease in the stomach, the primary 
tumor site. Overall there were 36% pathological 
complete remission (pCR) of the primary tumor site. 
Absolute median survival is reached at 28.8 months, 
81 % ( 9/11) survived beyond 18 months.
Table IC demonstrates that pCR have been achieved 
in all areas of the stomach. Distal stomach including 
fundus and corpus appears to be a more d iff ic u lt  
challenge for this treatment. Radiation as salvage 
produced pCR in the tumor of fundus and distal 
stomach, its role is confirmed again as effective 
against tumors of the proximal stomach.
Case Age Size Location Hist. Grade Treatment Survival (months) Outcome
1 40 T3 GE Junction Moderate MLPF! PFVelbane/42Gy 11 M
2 48 T4 Proximal Moderate MLPF/MLF! PFVelbane/45Gy 2 0 pCR
3
CMCO T4 Fundus Poor PLF/41 Gy 18 pCR
4 74 T4 Fundus Poor MLF 50 m
5 69 T4 Proximal Moderate MLPFIPLF 40Gy 44+ m,0/8 LN
6 73 T4 Corpus Moderate PLF 42+ m,0/35 LN
7 73 T4 Fundus Poor MLPF 29 m.0/5 LN
8 66 T4 Distal Moderate PLF/32Gy 26+ m,1/23 LN
9 69 T4 Distal Poor PLF/45Gy 27+ pCR
10 53 T3 GE Junction Poor PLF/45Gy 25+ pCR
11 60 T3 Distal Poor MLPF! PLF/36Gy 25+ M
rrrlocal disease, M:metastatic disease, pCR: pathological complete remission, LN: lymph node, m: minimal residual disease.
Table I C. Response characteristics at each location
Location # Tumor Status 
(Local)
Metastasized 
Lymph Nodes
Distant
Metastasis
pCRs in 
Radiation Tx
Gastro-Esophageal Junction 2 1 pCR n/a 1M 1 pCR/2
Proximal 2 1m, 1 pCR 0/8 - 1 pCR/2
Fundus 3 2m,1pCR 0/5 - 1 pCR/1
Corpus 1 1m 0/35 - -
Distal 3 1m,1pCR 1/23 1M 1 pCR/3
m: local disease: M: metastatic disease pCR: pathological complete remission, m: minimal residual disease, n/a: not available
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DISCUSSION
Prior neoadjuvant efforts for patients with tumors of the 
true stomach (not gastroesophageal junction) rarely 
yielded pCR (3,5-8). Our experience suggests 
individualized and sequential especially CMT efforts 
warrant testing and development because they 
appear to improve the rates of resectability and pCR. 
It is apparently possible to achieve pCR even after 
initial néoadjuvant attempts failed. This and our 
experience with pancreatic cancers suggest further 
emphasis on examination of novel forms of sequential 
therapy and In particular multidrug chemotherapy used 
simultaneously with split course radiation treatment 
(9,12-14). These novel chemotherapy regimens have 
proven components and promising results against 
metastatic disease, especially intraperitoneal disease 
(15). There is a case for testing new forms of 
chemotherapy especially methotrexate's direct activity 
and its ability to produce biochemical modulation. 
Cisplatin probably potentiates both methotrexate and 
fluorouracil with leucovorin in combination (15).
Conventional surgical methods normally find many 
involved lymph nodes in patients with T4 tumors, 
especially in the patients with poorly differentiated or 
obstructing lesions (2,3,9,10). The rarity of lymph node 
involvement (one involved node found in the entire 
series) suggests that neoadjuvant treatment often 
sterilizes lymph nodes. The observation suggests a 
role for further efforts to Improve the evaluation of 
apparently cancer free nodes by use of more sensitive 
methods i.e. fluorescent in situ hybridization (FISH) for 
evaluating the presence of tumor. None of these 
patients relapsed locally except the two which were not 
resected at surgery. This points to the continued 
importance of surgery as a therapeutic measure where 
cure is the goal. Ability to perform less extensive 
resection may be a quality of life and cost effective 
goal and another measure to be considered in 
comparing neoadjuvant therapies to standard primary 
surgery.
This experience confirmed that endoscopy is not 
entirely reliable following preoperative therapy (11). 
Radiologic and endoscopic ultrasound grossly 
underestimated the quality of the remissions. These 
tumors regress slowly and an inflammatory mass 
remains for months. The implication of these 
limitations - slow response and pseudo tumors- for 
design of treatment and for selecting the time of 
surgery clearly needs further consideration.
The peritoneum is widely viewed as the major site of 
failure when local control has been successful (2,10). 
This was true in the current series as well. Future 
efforts may integrate preoperative treatment measures 
which produce good local control with intraperitoneal
therapy. The successful response to second attempts 
at therapy represents an important new observation as 
may the degree of success in the use of radiation for 
some distal tumors (12-14). In theory the use of novel 
chemotherapy either before or concurrently with 
radiotherapy may improve the utility of radiotherapy. 
Prognostic evaluation may soon be improved by 
objective tests, specifically measurement of EGF (16) 
and abdominal fluid cytology (2). Also measurements 
of thymidilate synthase and other in vitro tests of tumor 
sensitivity may identify those tumors likely to benefit 
from adjuvant therapy (17,18).
It may be possible to improve quality of life and short 
term survival with neoadjuvant treatment: Quality of 
life, extent of surgery and sterilization of lymph nodes 
deserves evaluation as possible early indicators of 
benefit in new analyses of preoperative therapy.
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